Market Share of NA Pharmaceutical CMO Industry
The North America Pharmaceutical Contract Manufacturing Market is highly competitive as there is a robust presence of pharma and biotech research activity in the region. The consolidation of CMOs is expected to occur within the next few years, as the competitors will either leave the industry, or abandon a specific area within the industry, or go out of business. This improves the pricing power of value-added CMOs.
- May 2020 - Arcturus Therapeutics Holdings Inc. and Catalent, Inc. announced a partnership to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus. The production of LUNAR-COV19 at Catalent's state-of-the-art drug substance biomanufacturing facility in Madison, Wisconsin, will support human clinical studies and, if successful, commercialization of the vaccine.
- May 2020 - AbbVie announced that the U.S. Federal Trade Commission (FTC) had accepted the proposed consent order in connection with AbbVie's pending acquisition of Allergan. The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of Allergan by AbbVie.
North America Pharmaceutical Contract Manufacturing Market Leaders
Catalent Inc.
Pfizer CentreSource (Pfizer Inc.)
Baxter Biopharma Solutions (Baxter International Inc.)
Recipharm AB
AbbVie, Inc.
*Disclaimer: Major Players sorted in no particular order
